
TY  - JOUR
TI  - Australian Dental Research Foundation Special Research Supplement 2012
JO  - Australian Dental Journal
JA  - Aust Dent J
VL  - 57
IS  - 4
SN  - 0045-0421
UR  - https://doi.org/10.1111/adj.12014
DO  - doi:10.1111/adj.12014
SP  - S1
EP  - S53
PY  - 2012
ER  - 

TY  - JOUR
TI  - Poster Presentations - Poster Session 1: Sunday, 30 August 2009 - Monday, 31 August 2009
JO  - Transplant International
VL  - 22
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/j.1432-2277.2009.00958.x
DO  - doi:10.1111/j.1432-2277.2009.00958.x
SP  - 95
EP  - 222
PY  - 2009
ER  - 

TY  - JOUR
TI  - Thursday 9 July 2009 - Breakfast Meeting
JO  - Clinical Otolaryngology
VL  - 34
IS  - s1
SN  - 1749-4478
UR  - https://doi.org/10.1111/j.1749-4486.2009.01964_2.x
DO  - doi:10.1111/j.1749-4486.2009.01964_2.x
SP  - 13
EP  - 35
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts of the 20th International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management. Bordeaux, France, 22 - 25 August, 2004
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidem. Drug Safe.
VL  - 13
IS  - S1
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.987
DO  - doi:10.1002/pds.987
SP  - S1
EP  - S349
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstracts 1090 - 1621
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6135.2004.0480c.x
DO  - doi:10.1111/j.1600-6135.2004.0480c.x
SP  - 457
EP  - 604
PY  - 2004
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00025.x
DO  - doi:10.1111/j.1538-7836.2007.tb00025.x
SP  - O-T-001
EP  - O-T-096
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S7
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.13328
DO  - doi:10.1111/bcpt.13328
SP  - 3
EP  - 52
PY  - 2019
ER  - 

TY  - JOUR
TI  - Haemopoietic growth factors I
JO  - British Journal of Haematology
VL  - 81
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.1992.tb08268.x
DO  - doi:10.1111/j.1365-2141.1992.tb08268.x
SP  - 1
EP  - 429
PY  - 1992
ER  - 

TY  - JOUR
TI  - Hepatology Clinical
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 31
IS  - S2
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.13520
DO  - doi:10.1111/jgh.13520
SP  - 89
EP  - 120
PY  - 2016
ER  - 

TY  - JOUR
TI  - Discussed Poster Abstracts
JO  - Fundamental & Clinical Pharmacology
JA  - Fundam Clin Pharmacol
VL  - 32
IS  - S1
SN  - 0767-3981
UR  - https://doi.org/10.1111/fcp.12372
DO  - doi:10.1111/fcp.12372
SP  - 22
EP  - 56
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts for the 11th Meeting of the International Liver Transplantation Society, July 20–23, 2005, Los Angeles, California
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 11
IS  - 7
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.20473
DO  - doi:10.1002/lt.20473
SP  - C1
EP  - C166
PY  - 2005
ER  - 

TY  - JOUR
TI  - Proceedings of the Thrombosis and Hemostasis summit of North America: Research abstracts
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 87
IS  - S1
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.23168
DO  - doi:10.1002/ajh.23168
SP  - S146
EP  - S200
PY  - 2012
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 21
IS  - s1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.12495
DO  - doi:10.1111/ene.12495
SP  - 18
EP  - 103
PY  - 2014
ER  - 

TY  - JOUR
TI  - ARA Scientific Posters
JO  - Internal Medicine Journal
VL  - 37
IS  - s2
SN  - 1444-0903
UR  - https://doi.org/10.1111/j.1445-5994.2007.01428.x
DO  - doi:10.1111/j.1445-5994.2007.01428.x
SP  - A33
EP  - A57
PY  - 2007
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - Vox Sanguinis
VL  - 96
IS  - s1
SN  - 0042-9007
UR  - https://doi.org/10.1111/j.1423-0410.2009.01156.x
DO  - doi:10.1111/j.1423-0410.2009.01156.x
SP  - 63
EP  - 260
PY  - 2009
ER  - 

TY  - JOUR
TI  - 10th International Conference on Frontotemporal Dementias Munich/Germany; August 31-September 2, 2016
JO  - Journal of Neurochemistry
JA  - J. Neurochem.
VL  - 138
IS  - S1
SN  - 0022-3042
UR  - https://doi.org/10.1111/jnc.13692
DO  - doi:10.1111/jnc.13692
SP  - 222
EP  - 428
PY  - 2016
ER  - 

TY  - JOUR
TI  - Paper Poster Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 21
IS  - s1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.12497
DO  - doi:10.1111/ene.12497
SP  - 388
EP  - 713
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Asia-Pacific Journal of Clinical Oncology
JA  - Asia‐Pac J Clin Oncol
VL  - 10
IS  - S9
SN  - 1743-7555
UR  - https://doi.org/10.1111/ajco.12332
DO  - doi:10.1111/ajco.12332
SP  - 1
EP  - 264
PY  - 2014
ER  - 

AU  - Handler, Norbert
C7  - pp. 275-312
TI  - Pharmacophore Generation for Multiple Ligands
SN  - 9783527335381
UR  - https://doi.org/10.1002/9783527674381.ch10
DO  - doi:10.1002/9783527674381.ch10
SP  - 275-312
KW  - dual inhibitors
KW  - kinase inhibitors
KW  - ligand-based pharmacophore modeling
KW  - multiple ligands
KW  - pharmacophore generation
KW  - structure-based pharmacophore modeling
KW  - virtual screening
PY  - 2014
AB  - Summary In principle, for the development of pharmacophore models, two different approaches are known, the ligand-based and the structure-based approaches. Ligand-based pharmacophore modeling is an important tool for facilitating drug discovery in the absence of a macromolecular target structure. Structure-based pharmacophore modeling is based on the 3D structure of a macromolecule-ligand complex or a macromolecule without a ligand. As every virtual screening tool, also pharmacophore modeling very much depends on the data employed for model generation, refinement, and theoretical validation. This chapter describes the entire multiple ligand continuum from linked pharmacophore patterns to highly integrated examples including biological results to illustrate the broad spectrum of successful pathways for design and development of multiple ligands. It discusses the author's work to develop efficient kinase inhibitors to enable the development and characterization of further kinase targets and drugs.
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol.
VL  - 49
IS  - S38
SN  - 9783527335381
UR  - https://doi.org/10.1002/ppul.23108
DO  - doi:10.1002/ppul.23108
SP  - S216
EP  - S456
PY  - 2014
ER  - 
